Making the case for universal herpes zoster vaccination in older adults

Tolulope Famuyiro, Sarah Toombs Smith, Mukaila Raji

Research output: Contribution to journalReview article

Abstract

Reactivation of the varicella-zoster virus (VZV) causes herpes zoster (HZ, or shingles), which can lead to painful postherpetic neuralgia (PHN). Vaccination against HZ can reduce the occurrence of HZ and PHN, but vaccination rates are low in the older adult population, particularly among residents of long-term care (LTC) facilities, who are at highest risk of developing HZ and its potentially disabling and sometimes life-threatening sequelae. In addition, the live attenuated HZ vaccine (Zostavax, Merck & Co) is contraindicated in immunocompromised persons, a population that is highly represented in LTC settings. The recent availability of a newer non-live, recombinant, adjuvanted HZ vaccine (Shingrix, GlaxoSmithKline) offers the potential for a larger population to gain protection against VZV reactivation and its associated complications. Accordingly, we call for universal vaccination against HZ in the older adult population, especially among LTC residents. More real-world long-term studies are needed to assess the safety, adverse effects, and effectiveness of the non-live vaccine in the older old (persons aged 70 years or more), immunocompromised persons, and older adults with multimorbidity.

Original languageEnglish (US)
Pages (from-to)27-31
Number of pages5
JournalAnnals of Long-Term Care
Volume26
Issue number2
DOIs
StatePublished - Mar 1 2018

Fingerprint

Herpes Zoster
Vaccination
Long-Term Care
Postherpetic Neuralgia
Human Herpesvirus 3
Population
Vaccines
Herpes Zoster Vaccine
Attenuated Vaccines
Comorbidity
Safety

Keywords

  • Immunocompromisation
  • Older adults
  • Postherpetic neuralgia
  • Shingles
  • Vaccination
  • Varicella-zoster virus

ASJC Scopus subject areas

  • Gerontology
  • Geriatrics and Gerontology

Cite this

Making the case for universal herpes zoster vaccination in older adults. / Famuyiro, Tolulope; Smith, Sarah Toombs; Raji, Mukaila.

In: Annals of Long-Term Care, Vol. 26, No. 2, 01.03.2018, p. 27-31.

Research output: Contribution to journalReview article

Famuyiro, Tolulope ; Smith, Sarah Toombs ; Raji, Mukaila. / Making the case for universal herpes zoster vaccination in older adults. In: Annals of Long-Term Care. 2018 ; Vol. 26, No. 2. pp. 27-31.
@article{c9229721519e49fcac627c00c0477c9c,
title = "Making the case for universal herpes zoster vaccination in older adults",
abstract = "Reactivation of the varicella-zoster virus (VZV) causes herpes zoster (HZ, or shingles), which can lead to painful postherpetic neuralgia (PHN). Vaccination against HZ can reduce the occurrence of HZ and PHN, but vaccination rates are low in the older adult population, particularly among residents of long-term care (LTC) facilities, who are at highest risk of developing HZ and its potentially disabling and sometimes life-threatening sequelae. In addition, the live attenuated HZ vaccine (Zostavax, Merck & Co) is contraindicated in immunocompromised persons, a population that is highly represented in LTC settings. The recent availability of a newer non-live, recombinant, adjuvanted HZ vaccine (Shingrix, GlaxoSmithKline) offers the potential for a larger population to gain protection against VZV reactivation and its associated complications. Accordingly, we call for universal vaccination against HZ in the older adult population, especially among LTC residents. More real-world long-term studies are needed to assess the safety, adverse effects, and effectiveness of the non-live vaccine in the older old (persons aged 70 years or more), immunocompromised persons, and older adults with multimorbidity.",
keywords = "Immunocompromisation, Older adults, Postherpetic neuralgia, Shingles, Vaccination, Varicella-zoster virus",
author = "Tolulope Famuyiro and Smith, {Sarah Toombs} and Mukaila Raji",
year = "2018",
month = "3",
day = "1",
doi = "10.25270/altc.2018.04.00023",
language = "English (US)",
volume = "26",
pages = "27--31",
journal = "Annals of Long-Term Care",
issn = "1524-7929",
publisher = "HMP Communications LLP",
number = "2",

}

TY - JOUR

T1 - Making the case for universal herpes zoster vaccination in older adults

AU - Famuyiro, Tolulope

AU - Smith, Sarah Toombs

AU - Raji, Mukaila

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Reactivation of the varicella-zoster virus (VZV) causes herpes zoster (HZ, or shingles), which can lead to painful postherpetic neuralgia (PHN). Vaccination against HZ can reduce the occurrence of HZ and PHN, but vaccination rates are low in the older adult population, particularly among residents of long-term care (LTC) facilities, who are at highest risk of developing HZ and its potentially disabling and sometimes life-threatening sequelae. In addition, the live attenuated HZ vaccine (Zostavax, Merck & Co) is contraindicated in immunocompromised persons, a population that is highly represented in LTC settings. The recent availability of a newer non-live, recombinant, adjuvanted HZ vaccine (Shingrix, GlaxoSmithKline) offers the potential for a larger population to gain protection against VZV reactivation and its associated complications. Accordingly, we call for universal vaccination against HZ in the older adult population, especially among LTC residents. More real-world long-term studies are needed to assess the safety, adverse effects, and effectiveness of the non-live vaccine in the older old (persons aged 70 years or more), immunocompromised persons, and older adults with multimorbidity.

AB - Reactivation of the varicella-zoster virus (VZV) causes herpes zoster (HZ, or shingles), which can lead to painful postherpetic neuralgia (PHN). Vaccination against HZ can reduce the occurrence of HZ and PHN, but vaccination rates are low in the older adult population, particularly among residents of long-term care (LTC) facilities, who are at highest risk of developing HZ and its potentially disabling and sometimes life-threatening sequelae. In addition, the live attenuated HZ vaccine (Zostavax, Merck & Co) is contraindicated in immunocompromised persons, a population that is highly represented in LTC settings. The recent availability of a newer non-live, recombinant, adjuvanted HZ vaccine (Shingrix, GlaxoSmithKline) offers the potential for a larger population to gain protection against VZV reactivation and its associated complications. Accordingly, we call for universal vaccination against HZ in the older adult population, especially among LTC residents. More real-world long-term studies are needed to assess the safety, adverse effects, and effectiveness of the non-live vaccine in the older old (persons aged 70 years or more), immunocompromised persons, and older adults with multimorbidity.

KW - Immunocompromisation

KW - Older adults

KW - Postherpetic neuralgia

KW - Shingles

KW - Vaccination

KW - Varicella-zoster virus

UR - http://www.scopus.com/inward/record.url?scp=85060605648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060605648&partnerID=8YFLogxK

U2 - 10.25270/altc.2018.04.00023

DO - 10.25270/altc.2018.04.00023

M3 - Review article

VL - 26

SP - 27

EP - 31

JO - Annals of Long-Term Care

JF - Annals of Long-Term Care

SN - 1524-7929

IS - 2

ER -